Acta Med. 2018, 61: 79-85
https://doi.org/10.14712/18059694.2018.122
Endothelial Dysfunction in Children with Juvenile Psoriatic Arthritis
References
1. Ann Rheum Dis 2015; 74(2): 326–32.
< A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. https://doi.org/10.1136/annrheumdis-2014-205675>
<PubMed>
2. Arthritis Care Res 2015(7); 67: 1015–21.
< FC, Sánchez-Menéndez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based, cohort study. https://doi.org/10.1002/acr.22536>
<PubMed>
3. Arthritis Care Res 2017; 69(1): 67–74.
< A, Touma Z, Anderson M, Eder L. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. https://doi.org/10.1002/acr.22926>
4. J Intern Med 2011(2); 270: 147–57.
< O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. https://doi.org/10.1111/j.1365-2796.2010.02310.x>
5. Perm J 2008(4); 12: 4–8.
< S, Udaltsova N, Klatsky AL. Associations of psoriatic arthritis and cardiovascular conditions in a large population. https://doi.org/10.7812/TPP/07-141>
6. Ann Rheum Dis 2009; 68(7): 1131–5.
< DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. https://doi.org/10.1136/ard.2008.094839>
7. J Rheumatol 2006; 33(11): 2167–72.
C, Robinson DW Jr., Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
8. Ann Rheum Dis 2015; 74(2): 326–32.
< A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. https://doi.org/10.1136/annrheumdis-2014-205675>
<PubMed>
9. Ann Rheum Dis 2016; 75(5): 819–24.
< AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag Health Study. https://doi.org/10.1136/annrheumdis-2014-206824>
10. Ann Rheum Dis 2014; 73: 730–1.
< A, Cohen A, Bitterman H, et al. Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based cohort study. https://doi.org/10.1136/annrheumdis-2014-eular.3830>
11. Br J Dermatol 2012; 166(4): 811–8.
< WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in US women: a cohort study. https://doi.org/10.1111/j.1365-2133.2011.10774.x>
<PubMed>
12. Arthritis Rheum 2010; 62 Suppl 10: 793.
TJ, Solomon DH, Karlson EW. The risk of myocardial infarction among patients with psoriatic arthritis.
13. Arch Dermatol Res 2006; 298(7): 321–8.
< DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. https://doi.org/10.1007/s00403-006-0703-z>
14. Arthritis Rheumatol 2015; 67 Suppl 10: 1057.
K, Forsblad-d’Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferntiated spondyloarthritis associated with an increased risk of cardiovascular disease?
15. Eur J Epidemiol 2004; 19(3): 225–30.
< L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. https://doi.org/10.1023/B:EJEP.0000020447.59150.f9>
16. J Rheumatol 2010; 37(3): 521–8.
< B, Belch JJ, Pullar T, Ogston S, Khan F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. https://doi.org/10.3899/jrheum.090417>
17. Acta Medica (Hradec Králové) 2014; 57(1): 21–7.
< K, Sharma SB, Singal A, Aggarwal A. Association of carotid intima- media thickness with leptin and apoliprotein b/apoliprotein a-I ratio reveals imminent predictors of subclinical atherosclerosis in psoriasis patients. https://doi.org/10.14712/18059694.2014.4>
18. Semin arthritis Rheum 2007; 36(4): 203–9.
< O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. https://doi.org/10.1016/j.semarthrit.2006.09.001>
19. J Hypertens 2005; 23(2): 233–46.
< H, Cockcroft JR, Deanfield J, et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. https://doi.org/10.1097/00004872-200502000-00001>
20. J Hypertens 2005; 23(1): 7–17.
< J, Donald A, Ferri C, et al. Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds. https://doi.org/10.1097/00004872-200501000-00004>
21. J Rheumatol 2004; 31(2): 390–2.
RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis.
22. Arthritis Rheumatism 1997; 40(7): 1202–9.
< EG, Ruperto N, Ravelli A, Lovell DJ, Felson D, Martini A. Preliminary definition of improvement in juvenile arthritis. https://doi.org/10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R>
23. Arthritis Rheum 1994; 37(12): 1761–9.
< G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. https://doi.org/10.1002/art.1780371209>
24. J Am Coll Cardiol 2002; 39(2): 257–65.
< MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force.Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. https://doi.org/10.1016/S0735-1097(01)01746-6>
25. Arthritis Rheum 2006; 54(11): 3564–72.
< ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. https://doi.org/10.1002/art.22173>
26. Curr Pharm Des 2014; 20(4): 513–28.
< EA, Follansbee MR, Armstrong EJ, Armstrong AW. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis. https://doi.org/10.2174/138161282004140213123852>
27. J Eur Acad Dermatol Venereol 2009; 23(1): 1–6.
< DD, Balci A, Karazincir S, et al. Increased carotid artery intima- media thickness and impaired endothelial function in psoriasis. https://doi.org/10.1111/j.1468-3083.2008.02936.x>
28. Clin Exp Rheumatol 2015; 33: 40–3.
A, Consolaro A, Schiappapietra B, Martini A. The conundrum of juvenile psoriatic arthritis.
29. Annu Rev Pathol 2006; 1: 297–329.
< GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. https://doi.org/10.1146/annurev.pathol.1.110304.100100>
30. Atherosclerosis 2007; 190(1): 1–9.
< M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. https://doi.org/10.1016/j.atherosclerosis.2006.07.011>
31. Ann Rheum Dis 2015; 74(3): 480–489.
< C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. https://doi.org/10.1136/annrheumdis-2014-206624>
<PubMed>
32. Antiinflamm Antiallergy Agents MedChem 2013; 12(1): 55–67.
< C, Martel-Pelletier J, Davy JM, et al. Cardiovascularadverse effects of anti-inflammatory drugs. https://doi.org/10.2174/1871523011312010008>
33. Rheumatology 2008; 47(1): 72–5.
< VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Longterm exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. https://doi.org/10.1093/rheumatology/kem311>
34. Rheumatology 2013; 52(1): 68–7.
< JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population- based study. https://doi.org/10.1093/rheumatology/kes353>
35. Drug Saf 2018; 41(5): 473–88.
< M, Choy E, Lula S, et al. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease. https://doi.org/10.1007/s40264-017-0628-9>
<PubMed>
36. J Dermatolog Treat 2015; 26(1): 7–15.
< L, Strohal R, Husni ME, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate- to-severe psoriasis and psoriatic arthritis. https://doi.org/10.3109/09546634.2013.860209>
37. Clin Rheumatol 2014; 33(6): 833–9.
L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in CV risk in RA patients treated with biologics or tofacitinib a cohort of 210 psoriatic arthritis patients.
38. Ann Rheum Dis 2014; 73: 734–5.
< C, Agca R, Trivino L, Vogelzang E, Nurmohamed MT. Effect of etanercept therapy on lipid profile in patients with psoriatic arthritis. https://doi.org/10.1136/annrheumdis-2014-eular.5166>
39. J Rheumatol 2013; 40(6): 943–8.
< S, Marcovecchio ML, Gaspari S, et al. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. https://doi.org/10.3899/jrheum.121281>
40. Arthritis Rheum 1998; 41(6): 1103–10.
< DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. https://doi.org/10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N>
41. Immunobiology 2013; 218(11): 1376–84.
< IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic anflammation associated with atherosclerosis. https://doi.org/10.1016/j.imbio.2013.06.005>
42. Trends Cardiovasc Med 2008; 18(6): 228–32.
< J, Ley K. Monocyte-endothelial cell interaction in the development of atherosclerosis. https://doi.org/10.1016/j.tcm.2008.11.004>
<PubMed>
43. Physiol Genomics 2007; 31(2): 216–27.
Tacer K, Kuzman D, Seliskar M, et al. TNF – alpha interferes with lipid homeostasis and activates acute and proatherogenic processes.
44. Clin Sci (Lond) 2009; 116: 219–30.
< H, Park Y, Chen X, et al. Role of anti TNF – alpha in vascular dysfunction. https://doi.org/10.1042/CS20080196>
<PubMed>
45. Circulation 2003; 108(24): 2957–63.
< N, McCarey DW, Capell H, McInnes IB. Explaining how “highgrade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. https://doi.org/10.1161/01.CIR.0000099844.31524.05>
46. Ann Rheum Dis 2010; 69(12): 2169–72.
< A, Martin P, Flynn E, et al. Investigation of type 1 diabetes and coeliac disease susceptibility loci for association with juvenile idiopathic arthritis. https://doi.org/10.1136/ard.2009.126938>
<PubMed>
47. Pediatr Endocrinol Diabetes Metab 2012; 18(3): 112–5.
J, Ciljaková M, Michnová Z, Turčan T. Chronic complications of diabetes mellitus related to the respiratory system.
48. Metabolism 2012; 61(6): 869–72.
< NM, Daniels SR, Claytor RP, et al. Physical activity is independently associated with multiple measures of arterial stiffness in adolescents and young adults. https://doi.org/10.1016/j.metabol.2011.10.016>
<PubMed>
49. J Rheumatol 2013; 40(6): 943–8.
< S, Marcovecchio ML, Gaspari S, et al. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. https://doi.org/10.3899/jrheum.121281>
50. Joint Bone Spine 2014; 81(5): 386–91.
< C, Demougeot C, Guillot X, Godfrin-Valnet M, Wendling D. Endothelial dysfunction in joint disease. https://doi.org/10.1016/j.jbspin.2014.01.014>
51. Scand J Rheumatol 2012; 41(3): 240–42.
< G, Hollan I, Forre O, et al. Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combinationwith a TNF-alpha inhibitor in rheumatoid arthritis patients. https://doi.org/10.3109/03009742.2012.656698>
52. Ann Rheum Dis 2009; 68(3): 362–66.
< IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor-alpha blockade. https://doi.org/10.1136/ard.2007.086777>
53. Clin Rheumatol 2010; 29(7): 763–70.
< A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. https://doi.org/10.1007/s10067-010-1402-x>